Chemistry:BAY-293
From HandWiki
BAY-293 is the first drug reported to act as an inhibitor of the guanine nucleotide exchange factor protein SOS1. It acts by preventing SOS1 from binding to its target protein KRAS. It has potential applications in the treatment of cancer, and has been widely used in cancer research.[1][2][3][4][5]
See also
- BI-3406
References
- ↑ "Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction". Proceedings of the National Academy of Sciences of the United States of America 116 (7): 2551–2560. February 2019. doi:10.1073/pnas.1812963116. PMID 30683722. Bibcode: 2019PNAS..116.2551H.
- ↑ "Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma". Acta Pharmacologica Sinica 43 (10): 2696–2708. October 2022. doi:10.1038/s41401-022-00897-4. PMID 35352018.
- ↑ "Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer". Exploration of Targeted Anti-Tumor Therapy 4 (5): 1027–1038. 2023. doi:10.37349/etat.2023.00178. PMID 38023987.
- ↑ "Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer". International Journal of Molecular Sciences 24 (2): 997. January 2023. doi:10.3390/ijms24020997. PMID 36674513.
- ↑ "KRAS-SOS-1 Inhibition as New Pharmacological Target to Counteract Anaplastic Thyroid Carcinoma (ATC)". International Journal of Molecular Sciences 26 (6): 2579. March 2025. doi:10.3390/ijms26062579. PMID 40141222.
 |  |
